Cancer Drugs
-
{
- All
- News
- Videos
-
US Turn To Indian Pharmaceuticals Amid Critical Cancer Drug Shortage
US has sought help from Indian pharmaceutical manufacturers to address a shortage of the cancer drug ifosfamide.
-
Exclusive: Biggest Pancreatic Cancer Breakthrough In 50 Years, Says Indian Doctor, Co-Author Of Global Clinical Trial
Daraxonrasib belongs to a new class of medicines known as RAS(ON) inhibitors. The drug targets the active form of RAS proteins, which help drive tumour growth and survival.
-
Ovarian Cancer Breakthrough: New Targeted Drug Extends Survival, Improves Quality Of Life
A breakthrough targeted therapy, mirvetuximab soravtansine, is offering new hope to women with hard-to-treat ovarian cancer. Studies show it extends survival, slows disease progression, shrinks tumours and improves quality of life compared to chemotherapy.
-
Smart Cancer Drug Can Shrink Tumours By 30% In Early Trial
In an early-stage (Phase 1) trial of 83 patients, the drug shrank tumours in 26 people. For 15 of those patients, their tumours shrank by at least 30%.
-
Which Cancers Does Keytruda Work On? Apollo Oncologists Explain Effectiveness
The Drug Controller General of India (DCGI) has approved Keytruda for multiple cancer types. As of recent approvals, it covers 14 indications across eight tumour types.
-
Which Cancers Does Keytruda Work On? Apollo Oncologists Explain Effectiveness
The Drug Controller General of India (DCGI) has approved Keytruda for multiple cancer types. As of recent approvals, it covers 14 indications across eight tumour types.
-
High Cost, Limited Access: How Counterfeit Keytruda Market Puts Cancer Patients At Risk
Keytruda, developed by Merck & Co., belongs to a class of drugs known as immune checkpoint inhibitors, which help the immune system identify and attack cancer cells.
-
High Cost, Limited Access: How Counterfeit Keytruda Market Puts Cancer Patients At Risk
Keytruda, developed by Merck & Co., belongs to a class of drugs known as immune checkpoint inhibitors, which help the immune system identify and attack cancer cells.
-
Oncologists Explain Why They Prescribe Keytruda To Cancer Patients, When And How It Works
Keytruda is approved by the Drug Controller General of India (DCGI) for multiple cancer types. As of recent approvals, it covers 14 indications across eight tumour types.
-
Oncologists Explain Why They Prescribe Keytruda To Cancer Patients, When And How It Works
Keytruda is approved by the Drug Controller General of India (DCGI) for multiple cancer types. As of recent approvals, it covers 14 indications across eight tumour types.
-
What Is Keytruda And Why Is Everyone Talking About It In India's Cancer Fight?
In India, Keytruda is approved by the Drug Controller General of India (DCGI) for multiple cancer types. As of recent approvals, it covers 14 indications across eight tumour types.
-
What Is Keytruda And Why Is Everyone Talking About It In India's Cancer Fight?
In India, Keytruda is approved by the Drug Controller General of India (DCGI) for multiple cancer types. As of recent approvals, it covers 14 indications across eight tumour types.
-
Cancer Drug Imfinzi Gets Indian Regulator's Approval For Use In First-Line Treatment
AstraZeneca Pharma India Limited on Tuesday said it has received permission from the Central Drugs Standard Control Organisation to sell and distribute Durvalumab solution for infusion used in cancer treatment.
-
Cancer Drug Imfinzi Gets Indian Regulator's Approval For Use In First-Line Treatment
AstraZeneca Pharma India Limited on Tuesday said it has received permission from the Central Drugs Standard Control Organisation to sell and distribute Durvalumab solution for infusion used in cancer treatment.
-
Tax Cuts On Cancer Drugs, Higher Tobacco Tax Can Boost Public Health: AIIMS Study
The Goods and Services Tax (GST) exemption of lifesaving cancer drugs and higher taxation on tobacco products are the steps aimed at strengthening public health in the country, according to a new study led by oncologists from
-
US Turn To Indian Pharmaceuticals Amid Critical Cancer Drug Shortage
US has sought help from Indian pharmaceutical manufacturers to address a shortage of the cancer drug ifosfamide.
-
Exclusive: Biggest Pancreatic Cancer Breakthrough In 50 Years, Says Indian Doctor, Co-Author Of Global Clinical Trial
Daraxonrasib belongs to a new class of medicines known as RAS(ON) inhibitors. The drug targets the active form of RAS proteins, which help drive tumour growth and survival.
-
Ovarian Cancer Breakthrough: New Targeted Drug Extends Survival, Improves Quality Of Life
A breakthrough targeted therapy, mirvetuximab soravtansine, is offering new hope to women with hard-to-treat ovarian cancer. Studies show it extends survival, slows disease progression, shrinks tumours and improves quality of life compared to chemotherapy.
-
Smart Cancer Drug Can Shrink Tumours By 30% In Early Trial
In an early-stage (Phase 1) trial of 83 patients, the drug shrank tumours in 26 people. For 15 of those patients, their tumours shrank by at least 30%.
-
Which Cancers Does Keytruda Work On? Apollo Oncologists Explain Effectiveness
The Drug Controller General of India (DCGI) has approved Keytruda for multiple cancer types. As of recent approvals, it covers 14 indications across eight tumour types.
-
Which Cancers Does Keytruda Work On? Apollo Oncologists Explain Effectiveness
The Drug Controller General of India (DCGI) has approved Keytruda for multiple cancer types. As of recent approvals, it covers 14 indications across eight tumour types.
-
High Cost, Limited Access: How Counterfeit Keytruda Market Puts Cancer Patients At Risk
Keytruda, developed by Merck & Co., belongs to a class of drugs known as immune checkpoint inhibitors, which help the immune system identify and attack cancer cells.
-
High Cost, Limited Access: How Counterfeit Keytruda Market Puts Cancer Patients At Risk
Keytruda, developed by Merck & Co., belongs to a class of drugs known as immune checkpoint inhibitors, which help the immune system identify and attack cancer cells.
-
Oncologists Explain Why They Prescribe Keytruda To Cancer Patients, When And How It Works
Keytruda is approved by the Drug Controller General of India (DCGI) for multiple cancer types. As of recent approvals, it covers 14 indications across eight tumour types.
-
Oncologists Explain Why They Prescribe Keytruda To Cancer Patients, When And How It Works
Keytruda is approved by the Drug Controller General of India (DCGI) for multiple cancer types. As of recent approvals, it covers 14 indications across eight tumour types.
-
What Is Keytruda And Why Is Everyone Talking About It In India's Cancer Fight?
In India, Keytruda is approved by the Drug Controller General of India (DCGI) for multiple cancer types. As of recent approvals, it covers 14 indications across eight tumour types.
-
What Is Keytruda And Why Is Everyone Talking About It In India's Cancer Fight?
In India, Keytruda is approved by the Drug Controller General of India (DCGI) for multiple cancer types. As of recent approvals, it covers 14 indications across eight tumour types.
-
Cancer Drug Imfinzi Gets Indian Regulator's Approval For Use In First-Line Treatment
AstraZeneca Pharma India Limited on Tuesday said it has received permission from the Central Drugs Standard Control Organisation to sell and distribute Durvalumab solution for infusion used in cancer treatment.
-
Cancer Drug Imfinzi Gets Indian Regulator's Approval For Use In First-Line Treatment
AstraZeneca Pharma India Limited on Tuesday said it has received permission from the Central Drugs Standard Control Organisation to sell and distribute Durvalumab solution for infusion used in cancer treatment.
-
Tax Cuts On Cancer Drugs, Higher Tobacco Tax Can Boost Public Health: AIIMS Study
The Goods and Services Tax (GST) exemption of lifesaving cancer drugs and higher taxation on tobacco products are the steps aimed at strengthening public health in the country, according to a new study led by oncologists from
